Amelle Shillington

Amelle L. Shillington, DO


  • Attending Physician, Division of Human Genetics
  • Associate Program Director, Medical Genetics and Genomics Residencies
  • Assistant Professor, UC Department of Pediatrics

About

Biography

I am a board certified clinical geneticist, and am an attending physician and assistant professor in the division of human genetics. My interests include the clinical evaluation and diagnosis of genetic syndromes and risk variants in children and adults with neurodevelopmental disorders including autism spectrum disorder, intellectual disability and psychiatric disease burden. The focus of my research is on increasing accessibility to genetic testing for patients with neurodevelopmental disorders. I have an interest in emerging technologies for clinical diagnosis of neurodevelopmental disorders and have active collaborations to explore long read genomic sequencing techniques. I am the site clinical geneticist for the SPARK Simon’s foundation research genomic sequencing for patients with autism and for the Autism Care Network PATH to Discovery Project.

Residency: Combined Pediatric Medical Genetics, Cincinnati Children’s Hospital, Cincinnati, OH, 2017-2021.

DO: University of North Texas, Fort Worth, TX, 2017.

BA: Psychology with Honors, University of Waterloo, Canada, 1996-2000.

Interests

Autism spectrum disorder; intellectual disability; neurodevelopmental disorders; psychiatric genetics

Services and Specialties

Genetics

Interests

Mendelian neurodevelopmental disorders; neurodevelopmental new gene discovery; psychiatric genetics; catatonia; autism; intellectual disability

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

A Case of Lateral Meningocele Syndrome without Lateral Meningoceles. Rubadeux, D; Owens, JW; Shillington, A. Molecular Syndromology. 2024; 15:328-332.

Arginine, glycine, and creatine supplementation improves symptoms in a female with creatine transporter deficiency. Tauer, K; Theile, C; Owens, JW; Cecil, KM; Shillington, A. Psychiatric Genetics. 2024; 34:86-90.

Evidence-based recruitment strategies for clinical research: Study personnel's and research participants' perceptions about successful methods of outreach for a U.S. Autism-Research Cohort. Goin-Kochel, RP; Lozano, I; Duhon, G; Marzano, G; Daniels, A; Law, JK; Diehl, K; Snyder, LA G; Feliciano, P; Chung, WK. Journal of Clinical and Translational Science. 2024; 8:e65.

Neurodevelopmental Disorders Including Autism Spectrum Disorder and Intellectual Disability as a Risk Factor for Delayed Diagnosis of Catatonia. Zappia, KJ; Shillington, A; Fosdick, C; Erickson, CA; Lamy, M; Dominick, KC. Journal of Developmental and Behavioral Pediatrics. 2024; 45:e137-e142.

Neurodevelopmental and other phenotypes recurrently associated with heterozygous BAZ2B loss-of-function variants. Sewani, S; Azamian, MS; Mendelsohn, BA; Mau-Them, FT; Réda, M; Nambot, S; Isidor, B; van der Smagt, JJ; Shen, JJ; Shillington, A; Kinali, M; Zhao, X; Lalani, SR; Scott, DA. American Journal of Medical Genetics, Part A. 2024; 194:e63445.

P351: Genetic testing for patients with neurodevelopmental disorders in the inpatient psychiatry setting may reduce hospital stays and improve behavioral outcomes. Shillington, A; White, L; Doberstein, R; Hopkin, R; Harris, K; Zappia, K; Lamy, M. 2024; 2:101245.

Non-canonical C-terminal variant of MeCP2 R344W exhibits enhanced degradation rate. Chai, Y; Lee, SS Y; Shillington, A; Du, X; Fok, CK M; Yeung, KC; Siu, GK Y; Yuan, S; Zheng, Z; Tsang, HW S; Gu, S; Chen, Y; Ye, T; Ip, JP K. IBRO Neuroscience Reports. 2023; 15:218-224.

Genetic syndromes are prevalent in patients with comorbid neurodevelopmental disorders and catatonia. Shillington, A; Zappia, KJ; White, L; Fosdick, C; Erickson, CA; Lamy, M; Dominick, KC. American Journal of Medical Genetics, Part A. 2023; 191:2716-2722.

Elucidating the clinical and molecular spectrum of SMARCC2-associated NDD in a cohort of 65 affected individuals. Bosch, E; Popp, B; Güse, E; Skinner, C; van der Sluijs, PJ; Maystadt, I; Pinto, AM; Renieri, A; Bruno, LP; Granata, S; Severino, M; Reis, A; Accogli, A; Vasileiou, G. Genetics in Medicine. 2023; 25:100950.

27.4 Catatonia in Neurodevelopmental Disorders and the Creation of a Neurobehavioral Catatonia Specialty Clinic. Dominick, KC; Zappia, K; Shillington, A; Fosdick, CM; Lamy, M; Erickson, CA. Journal of the American Academy of Child and Adolescent Psychiatry. 2023; 62:s366-s367.

From the Blog

‘Medical Mystery’: Cincinnati Children’s Diagnoses Child With Tango2
Genomics and Development

‘Medical Mystery’: Cincinnati Children’s Diagnoses Child With Tango2

Amelle L. Shillington, DO3/24/2022

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating